The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation
Open accessAbstract
Somatic activating mutations in the phosphatidylinositol‐3‐kinase/AKT/mTOR pathway underlie heterogeneous segmental overgrowth phenotypes. Because of the extreme differences among patients, we sought to characterize the phenotypic spectrum associated with different genotypes and mutation burdens, including a better understanding of associated complications and natural history. Historically, the clinical diagnoses in patients with PIK3CA activating mutations have included Fibroadipose hyperplasia or Overgrowth (FAO), Hemihyperplasia Multiple Lipomatosis (HHML), Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, Scoliosis/Skeletal and Spinal (CLOVES) syndrome, macrodactyly, Fibroadipose Infiltrating Lipomatosis, and the related megalencephaly syndromes, Megalencephaly‐Capillary Malformation (MCAP or M‐CM) and Dysplastic Megalencephaly (DMEG). A workshop was convened at the National Institutes of Health (NIH) to discuss and develop a consensus document regarding diagnosis and treatment of patients with PIK3CA‐associated somatic overgrowth disorders. Participants in the workshop included a group of researchers from several institutions who have been studying these disorders and have published their findings, as well as representatives from patient‐advocacy and support groups. The umbrella term of “PIK3CA‐Related Overgrowth Spectrum (PROS)” was agreed upon to encompass both the known and emerging clinical entities associated with somatic PIK3CA mutations including, macrodactyly, FAO, HHML, CLOVES, and related megalencephaly conditions. Key clinical diagnostic features and criteria for testing were proposed, and testing approaches summarized. Preliminary recommendations for a uniform approach to assessment of overgrowth and molecular diagnostic testing were determined. Future areas to address include the surgical management of overgrowth tissue and vascular anomalies, the optimal approach to thrombosis risk, and the testing of potential pharmacologic therapies. © 2014 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1
Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045906 · Cited by 1,053
A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome
Lindhurst, M. J., Sapp, J. C., Teer, J. K., Johnston, J. J., Finn, E. M., Peters, K., Turner, J., Cannons, J. L., Bick, D., Blakemore, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104017 · Cited by 903
Self-citationPTEN: One Gene, Many Syndromes
Eng, C. (2003) · Human Mutation · doi:10.1002/humu.10257 · Cited by 787
Finding of Rare Disease Genes (FORGE) Canada Consortium, Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2331 · Cited by 741
Self-citationDe novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly
Lee, J. H., Huynh, M., Silhavy, J. L., Kim, S., Dixon-Salazar, T., Heiberg, A., Scott, E., Bafna, V., Hill, K. J., Collazo, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2329 · Cited by 703
Neurofibromatosis Type 1 Revisited
Williams, V. C., Lucas, J., Babcock, M. A., Gutmann, D. H., Korf, B., & Maria, B. L. (2009) · Pediatrics · doi:10.1542/peds.2007-3204 · Cited by 695
Localization of the gene for Cowden disease to chromosome 10q22–23
Nelen, M. R., Padberg, G. W., Peeters, E. A. J., Lin, A. Y., Helm, B. V. D., Frants, R. R., Goulon, V., Goldstein, A. M., Reen, M. M. M. V., Eastern, D. F., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-114 · Cited by 668
Will the real Cowden syndrome please stand up: revised diagnostic criteria
Eng, C. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.828 · Cited by 566
Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome
Kurek, K. C., Luks, V. L., Ayturk, U. M., Alomari, A. I., Fishman, S. J., Spencer, S. A., Mulliken, J. B., Bowen, M. E., Yamamoto, G. L., Kozakewich, H. P. W., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.05.006 · Cited by 532
Self-citationSomatic activation of AKT3 causes hemispheric developmental brain malformations
Poduri, A., Evrony, G. D., Cai, X., Elhosary, P. C., Beroukhim, R., Lehtinen, M. K., Hills, L. B., Heinzen, E. L., Hill, A., Hill, R. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.010 · Cited by 478
Proteus syndrome: Diagnostic criteria, differential diagnosis, and patient evaluation
Biesecker, L. G., Happle, R., Mulliken, J. B., Weksberg, R., Graham, J. M., Viljoen, D. L., & Cohen, M. M. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990611)84:5<389::aid-ajmg1>3.0.co;2-o · Cited by 421
Self-citationRare cancer-specific mutations in PIK3CA show gain of function
Gymnopoulos, M., Elsliger, M.-A., & Vogt, P. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701005104 · Cited by 376
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
Lindhurst, M. J., Parker, V. E. R., Payne, F., Sapp, J. C., Rudge, S., Harris, J., Witkowski, A. M., Zhang, Q., Groeneveld, M. P., Scott, C. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.2332 · Cited by 325
Self-citationClinical delineation and natural history of the PIK3CA‐related overgrowth spectrum
Keppler‐Noreuil, K. M., Sapp, J. C., Lindhurst, M. J., Parker, V. E. R., Blumhorst, C., Darling, T., Tosi, L. L., Huson, S. M., Whitehouse, R. W., Jakkula, E., et al. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36552 · Cited by 305
Self-citationHafner, C., López-Knowles, E., Luis, N. M., Toll, A., Baselga, E., Fernández-Casado, A., Hernández, S., Ribé, A., Mentzel, T., Stoehr, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705218104 · Cited by 209
An Activating Mutation of AKT2 and Human Hypoglycemia
Hussain, K., Challis, B., Rocha, N., Payne, F., Minic, M., Thompson, A., Daly, A., Scott, C., Harris, J., Smillie, B. J. L., et al. (2011) · Science · doi:10.1126/science.1210878 · Cited by 178
Self-citationFrom syndrome families to functional genomics
Brunner, H. G., & van Driel, M. A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1383 · Cited by 175
Megalencephaly Syndromes and Activating Mutations in the PI3K‐AKT Pathway: MPPH and MCAP
MIRZAA, G. M., RIVIÈRE, J., & DOBYNS, W. B. (2013) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31361 · Cited by 172
Self-citationSomatic gain-of-function mutations in PIK3CA in patients with macrodactyly
Rios, J. J., Paria, N., Burns, D. K., Israel, B. A., Cornelia, R., Wise, C. A., & Ezaki, M. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds440 · Cited by 168
Self-citationPIK3CA Activating Mutations in Facial Infiltrating Lipomatosis
Maclellan, R. A., Luks, V. L., Vivero, M. P., Mulliken, J. B., Zurakowski, D., Padwa, B. L., Warman, M. L., Greene, A. K., & Kurek, K. C. (2013) · Plastic & Reconstructive Surgery · doi:10.1097/01.prs.0000436822.26709.7c · Cited by 121
Cohen, M. M., Neri, G., & Weksberg, R. (2001) · Cited by 117
CLOVES syndrome with thoracic and central phlebectasia: Increased risk of pulmonary embolism
Alomari, A. I., Burrows, P. E., Lee, E. Y., Hedequist, D., Mulliken, J. B., & Fishman, S. J. (2010) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.04.023 · Cited by 63
Self-citationFGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis
Groesser, L., Herschberger, E., Landthaler, M., et al. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10788.x · Cited by 37
Long-Term Follow-up of Progressive Macrodystrophia Lipomatosa
Ho, C. A., Herring, J. A., & Ezaki, M. (2007) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200705000-00025 · Cited by 24
Self-citation
Cited by
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Venot, Q., Blanc, T., Rabia, S. H., Berteloot, L., Ladraa, S., Duong, J.-P., Blanc, E., Johnson, S. C., Hoguin, C., Boccara, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0217-9 · Cited by 589
Phosphatidylinositol 3-kinase, growth disorders, and cancer
Goncalves, M. D., Hopkins, B. D., & Cantley, L. C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1704560 · Cited by 327
Definitions and classification of malformations of cortical development: practical guidelines
Severino, M., Geraldo, A. F., Utz, N., Tortora, D., Pogledic, I., Klonowski, W., Triulzi, F., Arrigoni, F., Mankad, K., Leventer, R. J., et al. (2020) · Brain · doi:10.1093/brain/awaa174 · Cited by 313
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
Self-citationPIK3CA variants selectively initiate brain hyperactivity during gliomagenesis
Yu, K., Lin, C.-C. J., Hatcher, A., Lozzi, B., Kong, K., Huang-Hobbs, E., Cheng, Y.-T., Beechar, V. B., Zhu, W., Zhang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1952-2 · Cited by 253
Metadata
- Authors
- Keppler‐Noreuil, K. M., Rios, J. J., Parker, V. E. R., Semple, R. K., Lindhurst, M. J., Sapp, J. C., Alomari, A., Ezaki, M., Dobyns, W., & Biesecker, L. G.
- Venue
- American Journal of Medical Genetics Part A
- Publisher
- Wiley
- Published
- 2014-12-31
- Volume
- 167
- Issue
- 2
- Pages
- 287-295
- ISSN
- 1552-4825 (ISSN-L)
- 1552-4833
- OpenAlex
- W2000566468
- Cited by
- 580
- References
- 24
- FWCI
- 23.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.